DSM creates a joint venture with Nenter & Co to manufacture vitamin E
Category: #business  By Nikita Chaurasia  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

DSM creates a joint venture with Nenter & Co to manufacture vitamin E
  • DSM is likely to acquire a 75 percent stake in the joint venture for about €135 million.
     
  • The new business will exclusively manufacture vitamin E for DSM

The Dutch nutrition firm DSM has reportedly announced that it is planning to form a joint venture with China’s Nenter & Co., Inc. As per trusted sources, DSM is likely to acquire 75 percent stake in the joint venture for about €135 million.

Reportedly, the joint venture will also include all Nenter’s production and related assets for vitamin E. Moreover, both the firms would refurbish and upgrade the facilities to secure a sustainable and supply of vitamin E.

Sources familiar with the development claim that the venture will have a minority shareholding in Nenter’s Shishou facility in Hubei and will acquire and operate vitamin E manufacturing facilities in Jingzhou, China. Reportedly, there will be a profit share deal in place between Nenter and the Heerlen-headquartered firm and the new joint venture would manufacture vitamin E exclusively for DSM.

According to a press release by DSM, Vitamin E has been well-recognized and accepted as nature’s most effective chain-breaking, fat-soluble antioxidant, safeguarding cellular membranes from being damaged by lipid peroxyl radicals. The statement further noted that vitamin E maintains the structural integrity of all tissues and contributes substantially to optimum health. Apart from being an efficacious biological antioxidant, it also contributes to disease resistance of farm animals owing to modulating effects on the immune system.

For the record, DSM currently manufactures vitamin E in Switzerland and the joint venture will reportedly allow the company to simplify its supply chain by expanding manufacturing to the Asia Pacific region.

Reportedly, the joint venture agreement is expected to conclude in the second or third quarter of 2019, subject to several regulatory approvals.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...